Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer.
Ontology highlight
ABSTRACT: Patients with localized prostate cancer (PCa) have several therapeutic options with good prognosis. However, survival of patients with high-risk, advanced PCa is significantly less than patients with early-stage, organ-confined disease. Testosterone and other androgens have been directly linked to PCa progression since 1941. In this review, we chronicle the discoveries that led to modern therapeutic strategies for PCa. Specifically highlighted is the biology of androgen receptor (AR), the nuclear receptor transcription factor largely responsible for androgen-stimulated and castrate-recurrent (CR) PCa. Current PCa treatment paradigms can be classified into three distinct but interrelated categories: targeting AR at pre-receptor, receptor, or post-receptor signaling. The continuing challenge
SUBMITTER: Wadosky KM
PROVIDER: S-EPMC4807161 | biostudies-literature | 2016
REPOSITORIES: biostudies-literature
ACCESS DATA